EZZ Life Science Holdings delivered a robust Q2 FY25 with a 16.6% increase in customer receipts and a 308% jump in operating cash flows, while gearing up for US market entry and expanding its global footprint.
Advance ZincTek reports steady profit before tax for H1 FY25, driven by strong North American growth and significant cost savings following its Perth facility closure.